2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-117507
    U92016A hydrochloride 149654-41-1 98%
    U92016A hydrochloride is a potent, metabolically stable, orally acitive 5-HT1A receptor agonist with an exceptionally high degree of intrinsic activity. U92016A hydrochloride binds with high affinity to human 5-HT1A receptors expressed in Chinese hamster ovary cells (Ki=0.2 nM).
    U92016A hydrochloride
  • HY-117526
    (-)-Mesembrine 24880-43-1 98%
    (-)-Mesembrine, a psychoactive alkaloid, is a partial racemate in S. strictum and S. tortuosum in smaller amounts.
    (-)-Mesembrine
  • HY-117533
    UNC0006 1354030-14-0 98%
    UNC0006 is a β-arrestin-biased dopamine D2 ligand. UNC0006 can be used in the study of antipsychotic.
    UNC0006
  • HY-117542
    D595 16740-29-7 98%
    D595 is a phenylethylamine calcium channel blocker with potent negative inotropic activity. D595 has shown significant efficacy in its corresponding pharmacological studies, especially in inhibiting the uptake of monoamine neurotransmitters. D595 has high affinity in binding to the dopamine transporter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET). Structural adjustments of D595, especially changes in the hydroxyl stereochemistry, significantly affect its interaction with the transporters, showing a specific preference for stereoisomers.
    D595
  • HY-117560
    PWZ-029 164025-33-6 98%
    PWZ-029 is a selective inverse agonist for α5 GABAA receptors. PWZ-029 can improve object recognition in normal and scopolamine-treated rat model.
    PWZ-029
  • HY-117575
    WAY-100135 133025-23-7 98%
    WAY-100135 is a serotonergic compound belonging to the phenylpiperazine family, utilized in scientific research for its role as a strong antagonist of the 5-HT1A receptor and a partial agonist of the 5-HT1D receptor, with minimal activity at the 5-HT1B receptor.
    WAY-100135
  • HY-117578
    KB 5666 131916-69-3 98%
    KB 5666 is a benzoxazine derivative with lipid peroxidation inhibitory activity. KB 5666 showed protective effects against post-ischemic neuronal death. KB 5666 effectively protected CA1 neurons when injected 5 minutes before or immediately after ischemia. KB 5666 also showed a dose-dependent protective effect when injected within 1 hour after ischemia. KB 5666 effectively prevented the significant decrease in microtubule-associated protein 2 immunoreactivity within the dendritic field of CA1 pyramidal cells. KB 5666 prevented the decrease in [3H]PDBu binding activity in different layers of the CA1 region after ischemia. The application of KB 5666 showed the ability to improve the cellular and functional consequences of ischemia.
    KB 5666
  • HY-117606
    LY3027788 1377615-76-3 98%
    LY3027788, a diester analog of LY3020371 which is an mGlu2/3 receptor antagonist, is a potent and orally active prodrug of LY3020371. LY3027788 has antidepressant efficacy.
    LY3027788
  • HY-117609
    UE2343 1346013-80-6 98%
    UE2343 is an orally available, brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor. UE2343 is being investigated for the treatment of Alzheimer's disease.
    UE2343
  • HY-117611
    GAT107 1476807-74-5 98%
    GAT107 (compound 1b) is a potent α7 nAChR ago-PAMs (positive allosteric modulators).
    GAT107
  • HY-117637
    ALS-I-41 1369357-99-2 98%
    ALS-I-41 is a novel, potent and selective oxytocin receptor antagonist with the potential to modulate biological activities related to social behavior and mental disorders. ALS-I-41 is being evaluated for behavioral pharmacology experiments in non-human primates and can be administered via intranasal or intramuscular injection. The central nervous system penetration and metabolic rate of ALS-I-41 were studied by mass spectrometry analysis in cerebrospinal fluid and plasma of macaque monkeys.
    ALS-I-41
  • HY-117646
    FG-5893 150527-23-4 98%
    FG-5893 is a 5-HT1A receptor agonist and a 5-HT2 receptor antagonist. FG-5893 has anxiolytic effect.
    FG-5893
  • HY-117670
    PD-161182 168570-35-2 98%
    PD-161182 is a non-peptide NK-3 antagonist. PD-161182 can be studied in NK-3-related central nervous system disturbances, pain, inflammation, pulmonary and skin diseases.
    PD-161182
  • HY-117694
    MK-8825 1380887-60-4 98%
    MK-8825 is an orally active, potent and selective CGRP receptor antagonist, which shows concentration-dependent inhibition of Capsaicin (HY-10448)-evoked dermal blood flow with an EC50 value of about 7.4 μM. MK-8825 inhibits CGRP-induced spontaneous nociceptive facial grooming behaviors, neuronal activation in the trigeminal nucleus, and systemic release of pro-inflammatory cytokines in a mouse model of acute orofacial masseteric muscle pain. MK-8825 is promising for research of acute migraine.
    MK-8825
  • HY-117714
    AZD-3161 1369501-46-1 98%
    AZD-3161 is a potent and selective blocker of NaV1.7 channel, with a pIC50 of 7.1. AZD-3161 can be used for the research of neuropathic and inflammatory pain.
    AZD-3161
  • HY-117739
    BRD1652 1597438-92-0 98%
    BRD1652 is a highly selective GSK3 inhibitor. BRD1652 can be used in the study of emotion-related diseases.
    BRD1652
  • HY-117764
    LSP4-2022 1413405-33-0 98%
    LSP4-2022 is a potent and brain-penetrant mGlu4-selective orthosteric agonist, with an EC50 of 0.11 μM. LSP4-2022 inhibits neurotransmission in cerebellar slices from wild-type but not mGlu4 receptor-knockout mice. LSP4-2022 shows pro-depressant activity.
    LSP4-2022
  • HY-117765
    RS-5773 129173-57-5 98%
    RS-5773 is a calcium channel inhibitor and a diltiazem congener. RS-5773 has antianginal effect and does not cause excessive hypotension or depression of atrioventricular conduction .
    RS-5773
  • HY-117774
    AHR-2244 hydrochloride 24677-84-7 98%
    AHR-2244 hydrochloride is a bioactive agent that acts against psychosis and anxiety. It selectively blocks CAR in mice, rats, and cats, and can reduce the lethality associated with amphetamine.
    AHR-2244 hydrochloride
  • HY-117785
    4’-Methoxy-α-ethylaminovalerophenone hydrochloride 17837-89-7 98%
    4’-Methoxy-α-ethylaminovalerophenone hydrochloride is structurally classified as a drug derivative.
    4’-Methoxy-α-ethylaminovalerophenone hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity